Evaluation of naloxone in laboratory tests predictive of clinical antipsychotic activity.
D000818:Animals; D014150:Antipsychotic Agents; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001362:Avoidance Learning / Q000187:drug effects; D003024:Clozapine / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects; D003913:Dextroamphetamine / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D009270:Naloxone / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D012559:Schizophrenia / Q000188:drug therapy; D013045:Species Specificity; D013239:Stereotyped Behavior / Q000187:drug effects
D014150:Antipsychotic Agents; D009270:Naloxone; D003024:Clozapine; D006220:Haloperidol; D001058:Apomorphine; D003913:Dextroamphetamine